{"id":2490,"date":"2018-01-09T17:38:18","date_gmt":"2018-01-09T12:08:18","guid":{"rendered":"https:\/\/www.delveinsight.com\/blog\/?p=2490"},"modified":"2023-06-14T09:34:20","modified_gmt":"2023-06-14T04:04:20","slug":"notizia-63","status":"publish","type":"post","link":"https:\/\/www.delveinsight.com\/blog\/notizia-63","title":{"rendered":"Notizia"},"content":{"rendered":"<div id=\"ez-toc-container\" class=\"ez-toc-v2_0_76 counter-hierarchy ez-toc-counter ez-toc-white ez-toc-container-direction\">\n<p class=\"ez-toc-title\" style=\"cursor:inherit\">Table of Contents<\/p>\n<label for=\"ez-toc-cssicon-toggle-item-6a067d686529d\" class=\"ez-toc-cssicon-toggle-label\"><span class=\"\"><span class=\"eztoc-hide\" style=\"display:none;\">Toggle<\/span><span class=\"ez-toc-icon-toggle-span\"><svg style=\"fill: #999;color:#999\" xmlns=\"http:\/\/www.w3.org\/2000\/svg\" class=\"list-377408\" width=\"20px\" height=\"20px\" viewBox=\"0 0 24 24\" fill=\"none\"><path d=\"M6 6H4v2h2V6zm14 0H8v2h12V6zM4 11h2v2H4v-2zm16 0H8v2h12v-2zM4 16h2v2H4v-2zm16 0H8v2h12v-2z\" fill=\"currentColor\"><\/path><\/svg><svg style=\"fill: #999;color:#999\" class=\"arrow-unsorted-368013\" xmlns=\"http:\/\/www.w3.org\/2000\/svg\" width=\"10px\" height=\"10px\" viewBox=\"0 0 24 24\" version=\"1.2\" baseProfile=\"tiny\"><path d=\"M18.2 9.3l-6.2-6.3-6.2 6.3c-.2.2-.3.4-.3.7s.1.5.3.7c.2.2.4.3.7.3h11c.3 0 .5-.1.7-.3.2-.2.3-.5.3-.7s-.1-.5-.3-.7zM5.8 14.7l6.2 6.3 6.2-6.3c.2-.2.3-.5.3-.7s-.1-.5-.3-.7c-.2-.2-.4-.3-.7-.3h-11c-.3 0-.5.1-.7.3-.2.2-.3.5-.3.7s.1.5.3.7z\"\/><\/svg><\/span><\/span><\/label><input type=\"checkbox\"  id=\"ez-toc-cssicon-toggle-item-6a067d686529d\"  aria-label=\"Toggle\" \/><nav><ul class='ez-toc-list ez-toc-list-level-1 ' ><li class='ez-toc-page-1 ez-toc-heading-level-4'><a class=\"ez-toc-link ez-toc-heading-1\" href=\"https:\/\/www.delveinsight.com\/blog\/notizia-63\/#Key_to_new_Cancer_drugs_discovered_in_bacterial_genomes\" >Key to new Cancer drugs discovered in bacterial genomes<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-4'><a class=\"ez-toc-link ez-toc-heading-2\" href=\"https:\/\/www.delveinsight.com\/blog\/notizia-63\/#New_Research_paper_could_increase_pressure_on_CRISPR_biotechs\" >New Research paper could increase pressure on CRISPR biotechs<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-4'><a class=\"ez-toc-link ez-toc-heading-3\" href=\"https:\/\/www.delveinsight.com\/blog\/notizia-63\/#Clinical_trials_to_be_initiated_for_BioAtlas_Conditionally_Active_Biologics_in_CAR-T_Candidates_for_Solid_Tumors_in_China\" >Clinical trials to be initiated for BioAtla&#8217;s Conditionally Active Biologics in CAR-T Candidates for Solid Tumors in China<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-4'><a class=\"ez-toc-link ez-toc-heading-4\" href=\"https:\/\/www.delveinsight.com\/blog\/notizia-63\/#Ascentage_Pharma_has_recently_got_acceptance_of_IND_application_by_China_FDA_for_Clinical_Study_of_Novel_IAP_Inhibitor_for_treating_Hepatitis_B_infection\" >Ascentage Pharma has recently got acceptance of IND application by China FDA for Clinical Study of Novel IAP Inhibitor for treating Hepatitis B infection<\/a><\/li><\/ul><\/nav><\/div>\n<h4 style=\"text-align: justify;\"><span class=\"ez-toc-section\" id=\"Key_to_new_Cancer_drugs_discovered_in_bacterial_genomes\"><\/span>Key to new Cancer drugs discovered in bacterial genomes<span class=\"ez-toc-section-end\"><\/span><\/h4>\n<p style=\"text-align: justify;\">Achievement is made by the scientists of The Scripps Research Institute (TSRI) Florida campus who had previously&nbsp;discovered LNM E1 compound used to kill prostate cancer. This time they have unlocked the capability of LNM family molecules by \u201cmining\u201d the information stored in bacterial genomes and bringing them even closer to the clinical trials. Present research results suggest that these hidden genes hold the key to developing new, even more, effective cancer-targeting compounds.<\/p>\n<h4 style=\"text-align: justify;\"><span class=\"ez-toc-section\" id=\"New_Research_paper_could_increase_pressure_on_CRISPR_biotechs\"><\/span>New Research paper could increase pressure on CRISPR biotechs<span class=\"ez-toc-section-end\"><\/span><\/h4>\n<p style=\"text-align: justify;\">Recently published paper in a journal has revealed that a \u201ccutting\u201d element of the CRISPR-Cas9 gene-editing technique could be considered as a potential threat to body\u2019s own immune system.<\/p>\n<p style=\"text-align: justify;\">Paper published on bioRxiv (yet to be reviewed), saw researchers result on blood tests taken from a few dozen people.&nbsp;Results have shown the presence of pre-existing adaptive immune responses in humans to either Cas9 homolog that may hinder the efficacious and safe use of the Cas9\/gRNA system to treat disease and might result in significant toxicity to host.<\/p>\n<h4 style=\"text-align: justify;\"><span class=\"ez-toc-section\" id=\"Clinical_trials_to_be_initiated_for_BioAtlas_Conditionally_Active_Biologics_in_CAR-T_Candidates_for_Solid_Tumors_in_China\"><\/span>Clinical trials to be initiated for BioAtla&#8217;s Conditionally Active Biologics in CAR-T Candidates for Solid Tumors in China<span class=\"ez-toc-section-end\"><\/span><\/h4>\n<p style=\"text-align: justify;\">Global biotechnology company BioAtla, LLC, focused on the development of Conditionally Active Biologic (CAB) protein therapeutics has recently announced that Shanghai Sinobioway Sunterra Biotechnology has received ethics committee approval of a clinical trial for two novel, conditionally active chimeric antigen receptor T cell (CAB-CAR-T) products. The drug candidates are designed to target Axl and Ror2 for the treatment of metastatic renal cell carcinoma.<\/p>\n<h4 style=\"text-align: justify;\"><span class=\"ez-toc-section\" id=\"Ascentage_Pharma_has_recently_got_acceptance_of_IND_application_by_China_FDA_for_Clinical_Study_of_Novel_IAP_Inhibitor_for_treating_Hepatitis_B_infection\"><\/span>Ascentage Pharma has recently got acceptance of IND application by China FDA for Clinical Study of Novel IAP Inhibitor for treating Hepatitis B infection<span class=\"ez-toc-section-end\"><\/span><\/h4>\n<p style=\"text-align: justify;\">The global clinical-stage biopharmaceutical company, Ascentage Pharma dedicated to developing apoptosis-targeted therapies for cancers and other diseases has recently announced the CFDA approval of the IND application for APG-1387. It is a novel small molecule IAP inhibitor under-development for the treatment of the Hepatitis B virus (HBV) infection. It is the first IAP inhibitor to be studied in patients with HBV in China. As China accounts for approximately one-third of HBV carriers globally.<\/p>\n","protected":false},"excerpt":{"rendered":"<p>Key to new Cancer drugs discovered in bacterial genomes Achievement is made by the scientists of The Scripps Research Institute (TSRI) Florida campus who had previously&nbsp;discovered LNM E1 compound used to kill prostate cancer. This time they have unlocked the capability of LNM family molecules by \u201cmining\u201d the information stored in bacterial genomes and bringing [&hellip;]<\/p>\n","protected":false},"author":1,"featured_media":2465,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"_editorskit_title_hidden":false,"_editorskit_reading_time":1,"_editorskit_is_block_options_detached":false,"_editorskit_block_options_position":"{}","advgb_blocks_editor_width":"","advgb_blocks_columns_visual_guide":"","footnotes":""},"categories":[32],"tags":[1272,1278,1168,1167,137,988,810,1274,169,647,1390,190,204,1271,1277,1964,1275,1276,1273,1280,730,639,1183,1279],"industry":[17225],"therapeutic_areas":[17235,17231,17228],"class_list":["post-2490","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-notizia","tag-ascentage-pharma","tag-bioatlas","tag-business-consultancy","tag-business-consultants","tag-cancer","tag-cancer-drugs","tag-car-t","tag-china-fda","tag-clinical-trials","tag-crispr","tag-crispr-therapeutics","tag-crispr-cas9","tag-delveinsight","tag-delveinsight-pharma-news","tag-hbv","tag-hepatitis-b","tag-hepatitis-b-infection","tag-iap-inhibitor","tag-ind-application","tag-lnm-e1","tag-notizia","tag-pharma-news","tag-pharmaceutical-news","tag-the-scripps-research-institute-tsri","industry-pharmaceutical","therapeutic_areas-cell-and-gene-therapy","therapeutic_areas-infectious-diseases","therapeutic_areas-oncology"],"acf":[],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v25.8 (Yoast SEO v25.8) - https:\/\/yoast.com\/wordpress\/plugins\/seo\/ -->\n<title>Notizia-Latest pharma news by Delveinsight Business Research LLP<\/title>\n<meta name=\"description\" content=\"The Scripps Research Institute(TSRI) Florida campus who had previously discovered LNM E1 compound used to kill prostate cancer have made another achievement\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.delveinsight.com\/blog\/notizia-63\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Notizia-Latest pharma news by Delveinsight Business Research LLP\" \/>\n<meta property=\"og:description\" content=\"The Scripps Research Institute(TSRI) Florida campus who had previously discovered LNM E1 compound used to kill prostate cancer have made another achievement\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.delveinsight.com\/blog\/notizia-63\" \/>\n<meta property=\"og:site_name\" content=\"DelveInsight Business Research\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/DelveInsight-1423323754607782\/\" \/>\n<meta property=\"article:published_time\" content=\"2018-01-09T12:08:18+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2023-06-14T04:04:20+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2017\/12\/09021225\/Notizia.png\" \/>\n\t<meta property=\"og:image:width\" content=\"1112\" \/>\n\t<meta property=\"og:image:height\" content=\"660\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"author\" content=\"DelveInsight\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:creator\" content=\"@DelveInsight\" \/>\n<meta name=\"twitter:site\" content=\"@DelveInsight\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"DelveInsight\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Notizia-Latest pharma news by Delveinsight Business Research LLP","description":"The Scripps Research Institute(TSRI) Florida campus who had previously discovered LNM E1 compound used to kill prostate cancer have made another achievement","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.delveinsight.com\/blog\/notizia-63","og_locale":"en_US","og_type":"article","og_title":"Notizia-Latest pharma news by Delveinsight Business Research LLP","og_description":"The Scripps Research Institute(TSRI) Florida campus who had previously discovered LNM E1 compound used to kill prostate cancer have made another achievement","og_url":"https:\/\/www.delveinsight.com\/blog\/notizia-63","og_site_name":"DelveInsight Business Research","article_publisher":"https:\/\/www.facebook.com\/DelveInsight-1423323754607782\/","article_published_time":"2018-01-09T12:08:18+00:00","article_modified_time":"2023-06-14T04:04:20+00:00","og_image":[{"width":1112,"height":660,"url":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2017\/12\/09021225\/Notizia.png","type":"image\/png"}],"author":"DelveInsight","twitter_card":"summary_large_image","twitter_creator":"@DelveInsight","twitter_site":"@DelveInsight","twitter_misc":{"Written by":"DelveInsight","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"WebPage","@id":"https:\/\/www.delveinsight.com\/blog\/notizia-63","url":"https:\/\/www.delveinsight.com\/blog\/notizia-63","name":"Notizia-Latest pharma news by Delveinsight Business Research LLP","isPartOf":{"@id":"https:\/\/www.delveinsight.com\/blog\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.delveinsight.com\/blog\/notizia-63#primaryimage"},"image":{"@id":"https:\/\/www.delveinsight.com\/blog\/notizia-63#primaryimage"},"thumbnailUrl":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2017\/12\/09021225\/Notizia.png","datePublished":"2018-01-09T12:08:18+00:00","dateModified":"2023-06-14T04:04:20+00:00","author":{"@id":"https:\/\/www.delveinsight.com\/blog\/#\/schema\/person\/5fbf6ca478835d03fdb5e17d905b520a"},"description":"The Scripps Research Institute(TSRI) Florida campus who had previously discovered LNM E1 compound used to kill prostate cancer have made another achievement","inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.delveinsight.com\/blog\/notizia-63"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.delveinsight.com\/blog\/notizia-63#primaryimage","url":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2017\/12\/09021225\/Notizia.png","contentUrl":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2017\/12\/09021225\/Notizia.png","width":1112,"height":660,"caption":"transthyretin amyloidosis"},{"@type":"WebSite","@id":"https:\/\/www.delveinsight.com\/blog\/#website","url":"https:\/\/www.delveinsight.com\/blog\/","name":"DelveInsight Business Research","description":"Blog","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.delveinsight.com\/blog\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.delveinsight.com\/blog\/#\/schema\/person\/5fbf6ca478835d03fdb5e17d905b520a","name":"DelveInsight","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.delveinsight.com\/blog\/#\/schema\/person\/image\/","url":"https:\/\/secure.gravatar.com\/avatar\/afdd550c64e18f6ad8957080b017c6ae55f4916951d641d3cd40264176aa0e86?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/afdd550c64e18f6ad8957080b017c6ae55f4916951d641d3cd40264176aa0e86?s=96&d=mm&r=g","caption":"DelveInsight"}}]}},"author_meta":{"display_name":"DelveInsight","author_link":"https:\/\/www.delveinsight.com\/blog\/author\/gtadmin"},"featured_img":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2017\/12\/09021225\/Notizia-300x178.png","coauthors":[],"tax_additional":{"categories":{"linked":["<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">Notizia - Recent Pharma, Healthcare and Biotech Happenings<\/a>"],"unlinked":["<span class=\"advgb-post-tax-term\">Notizia - Recent Pharma, Healthcare and Biotech Happenings<\/span>"]},"tags":{"linked":["<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">Ascentage Pharma<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">BioAtla&#039;s<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">business consultancy<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">business consultants<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">Cancer<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">cancer drugs<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">CAR-T<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">China FDA<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">Clinical trials<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">CRISPR<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">CRISPR Therapeutics<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">CRISPR-Cas9<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">DelveInsight<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">delveinsight pharma news<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">HBV<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">hepatitis B<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">Hepatitis B infection<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">IAP Inhibitor<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">IND application<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">LNM E1<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">Notizia<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">pharma news<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">pharmaceutical news<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">The Scripps Research Institute (TSRI)<\/a>"],"unlinked":["<span class=\"advgb-post-tax-term\">Ascentage Pharma<\/span>","<span class=\"advgb-post-tax-term\">BioAtla&#039;s<\/span>","<span class=\"advgb-post-tax-term\">business consultancy<\/span>","<span class=\"advgb-post-tax-term\">business consultants<\/span>","<span class=\"advgb-post-tax-term\">Cancer<\/span>","<span class=\"advgb-post-tax-term\">cancer drugs<\/span>","<span class=\"advgb-post-tax-term\">CAR-T<\/span>","<span class=\"advgb-post-tax-term\">China FDA<\/span>","<span class=\"advgb-post-tax-term\">Clinical trials<\/span>","<span class=\"advgb-post-tax-term\">CRISPR<\/span>","<span class=\"advgb-post-tax-term\">CRISPR Therapeutics<\/span>","<span class=\"advgb-post-tax-term\">CRISPR-Cas9<\/span>","<span class=\"advgb-post-tax-term\">DelveInsight<\/span>","<span class=\"advgb-post-tax-term\">delveinsight pharma news<\/span>","<span class=\"advgb-post-tax-term\">HBV<\/span>","<span class=\"advgb-post-tax-term\">hepatitis B<\/span>","<span class=\"advgb-post-tax-term\">Hepatitis B infection<\/span>","<span class=\"advgb-post-tax-term\">IAP Inhibitor<\/span>","<span class=\"advgb-post-tax-term\">IND application<\/span>","<span class=\"advgb-post-tax-term\">LNM E1<\/span>","<span class=\"advgb-post-tax-term\">Notizia<\/span>","<span class=\"advgb-post-tax-term\">pharma news<\/span>","<span class=\"advgb-post-tax-term\">pharmaceutical news<\/span>","<span class=\"advgb-post-tax-term\">The Scripps Research Institute (TSRI)<\/span>"]}},"comment_count":"0","relative_dates":{"created":"Posted 8 years ago","modified":"Updated 3 years ago"},"absolute_dates":{"created":"Posted on Jan 9, 2018","modified":"Updated on Jun 14, 2023"},"absolute_dates_time":{"created":"Posted on Jan 9, 2018 5:38 pm","modified":"Updated on Jun 14, 2023 9:34 am"},"featured_img_caption":"transthyretin amyloidosis","series_order":"","_links":{"self":[{"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/posts\/2490","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/comments?post=2490"}],"version-history":[{"count":0,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/posts\/2490\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/media\/2465"}],"wp:attachment":[{"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/media?parent=2490"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/categories?post=2490"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/tags?post=2490"},{"taxonomy":"industry","embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/industry?post=2490"},{"taxonomy":"therapeutic_areas","embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/therapeutic_areas?post=2490"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}